The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents.

Journal of the American Medical Directors Association
Anton De SpiegeleerBart De Spiegeleer

Abstract

Angiotensin-converting enzyme inhibitors (ACEi), angiotensin II receptor blockers (ARBs), and HMG-CoA reductase inhibitors ("statins") have been hypothesized to affect COVID-19 severity. However, up to now, no studies investigating this association have been conducted in the most vulnerable and affected population groups (ie, older adults residing in nursing homes). The objective of this study was to explore the association of ACEi/ARB and/or statins with clinical manifestations in COVID-19-infected older adults residing in nursing homes. We undertook a retrospective multicenter cohort study to analyze the association between ACEi/ARB and/or statin use with clinical outcome of COVID-19. The outcomes were (1) serious COVID-19 defined as long-stay hospital admission or death within 14 days of disease onset, and (2) asymptomatic (ie, no disease symptoms in the whole study period while still being diagnosed by polymerase chain reaction). A total of 154 COVID-19-positive subjects were identified, residing in 1 of 2 Belgian nursing homes that experienced similar COVID-19 outbreaks. Logistic regression models were applied with age, sex, functional status, diabetes, and hypertension as covariates. We found a statistically significant a...Continue Reading

References

Jan 25, 2005·American Journal of Physiology. Lung Cellular and Molecular Physiology·Jeffrey R JacobsonJoe G N Garcia
Jul 8, 2005·Nature·Yumiko ImaiJosef M Penninger
Aug 25, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Eric M MortensenMichael J Fine
Nov 15, 2013·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·Roelie M Wösten-van AsperenRené Lutter
May 22, 2019·European Journal of Clinical Investigation·Suzanne Schol-GelokTeun van Gelder
Feb 20, 2020·Journal of Thrombosis and Haemostasis : JTH·Ning TangZiyong Sun
Mar 14, 2020·The Journal of Clinical Investigation·Arturo Casadevall, Liise-Anne Pirofski
Mar 17, 2020·Journal of Critical Care·Andrea CortegianiSharon Einav
Mar 19, 2020·The New England Journal of Medicine·Bin CaoChen Wang
Mar 24, 2020·JAMA : the Journal of the American Medical Association·Graziano OnderSilvio Brusaferro
Mar 29, 2020·The New England Journal of Medicine·Temet M McMichaelUNKNOWN Public Health–Seattle and King County, EvergreenHealth, and CDC COVID-19 Investigation Team
Apr 11, 2020·The New England Journal of Medicine·Jonathan GreinTimothy Flanigan
Apr 15, 2020·Ear, Nose, & Throat Journal·Andrea Lovato, Cosimo de Filippis
May 1, 2020·BMJ : British Medical Journal·Adrian O'Dowd
May 11, 2020·Journal of the American College of Cardiology·Ishan ParanjpeGirish N Nadkarni
May 14, 2020·Archives of Medical Science : AMS·Željko ReinerAmirhossein Sahebkar
May 23, 2020·Nature Reviews. Immunology·Laure-Anne TeuwenPeter Carmeliet

❮ Previous
Next ❯

Citations

Jul 24, 2020·Journal of Drug Targeting·Saghir AkhtarAbdella M Habib
Jul 29, 2020·International Journal of Molecular Sciences·Rami A Al-HoraniKholoud F Aliter
Jul 23, 2020·Drugs·John G RizkDonald N Forthal
Oct 17, 2020·Scientific Reports·Wilnard Y T TanRinkoo Dalan
Feb 6, 2021·Postgraduate Medical Journal·Rimesh PalSukrita Bhattacharjee
Dec 30, 2020·Journal of Molecular and Cellular Cardiology·Walid HamoucheLahouaria Hadri
Feb 6, 2021·Frontiers in Pharmacology·Alpo Vuorio, Petri T Kovanen
Feb 23, 2021·The Korean Journal of Internal Medicine·Sang Heon SuhEun Hui Bae
Mar 18, 2021·Immune Network·Erica EspañoJeong-Ki Kim
Aug 31, 2020·Heart & Lung : the Journal of Critical Care·Shekhar KunalSanjay Gupta
Mar 23, 2021·Mayo Clinic Proceedings. Innovations, Quality & Outcomes·Zachary A YetmarJohn C O'Horo
Apr 12, 2021·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·Timotius I Hariyanto, Andree Kurniawan
Apr 15, 2021·Clinics·Filipe FerrariRicardo Stein
Nov 4, 2020·Journal of the American Medical Directors Association·Bastien GenetOlivier Hanon
May 1, 2021·Journal of Clinical Medicine·Mike SathekgeDavid Fedson
May 1, 2021·Journal of Clinical Medicine·Chieh-Chen WuYung-Ching Weng
Apr 30, 2021·Progress in Lipid Research·Maria Chiara ProtoMaurizio Bifulco
May 7, 2021·Circulation Journal : Official Journal of the Japanese Circulation Society·Yuji IkariShingo Matsumoto
May 26, 2021·European Geriatric Medicine·Mariana AlvesUNKNOWN EuGMS Special Interest Group inCardiovascular Medicine (Chairpersons A. Ungar and A. Benetos)
May 29, 2021·Human Vaccines & Immunotherapeutics·Geert ByttebierDavid S Fedson
Jun 4, 2021·International Journal of Clinical Practice·Mohammad Haji AghajaniMohammad Sistanizad
Jun 22, 2021·Biochimie·Stéphane OrlowskiEric Bruckert
Jul 6, 2021·Journal of Diabetes and Metabolic Disorders·Yasaman SharifiMahbube Ebrahimpur
Jul 11, 2021·Atherosclerosis·Anastasios KolliasKonstantinos Syrigos

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Clinical Trials Mentioned

NCT04348695
NCT04343001
NCT04351581

Software Mentioned

R
SAS
RStudio

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.